Inovio (INO) Pharmaceuticals announced that it intends to offer and sell shares of its common stock, accompanying Series A warrants and Series B warrants to purchase shares of its common stock, in an underwritten public offering. All of the securities in the proposed offering will be sold by Inovio. Piper Sandler & Co. is acting as sole book-running manager for the offering.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INO:
- Inovio Pharmaceuticals Holds Annual Stockholders Meeting
- Inovio Pharmaceuticals’ Earnings Call: Progress Amid Challenges
- Inovio price target lowered to $13 from $15 at Oppenheimer
- Inovio Pharmaceuticals: Hold Rating Due to Financial Losses and Uncertain Development Timeline
- Inovio Pharmaceuticals Advances DNA Medicine Pipeline